Tandon N N, Ockenhouse C F, Greco N J, Jamieson G A
American Red Cross, Cell Biology Laboratory, Rockville, MD 20855.
Blood. 1991 Dec 1;78(11):2809-13.
Glycoprotein IV (GPIV; CD36 or GPIIIb) is a cell surface glycoprotein that has been proposed as mediating a number of physiologically important processes such as the adhesion of platelets to thrombospondin (TSP) and collagen, the cytoadherence of Plasmodium falciparum-infected erythrocytes, and the TSP-dependent interaction of monocytes with platelets and macrophages. Because platelets of the Naka-negative phenotype have recently been shown to lack detectable GPIV, their availability offered the opportunity to test directly these hypotheses regarding its adhesive functions. It has been found that Naka-negative platelets and monocytes do not support cytoadherence of P falciparum-infected erythrocytes. Naka-negative platelets are deficient in the initial stages of their adhesion to fibrillar collagen and this defect is most marked under Mg(2+)-free conditions. Finally, the ability of Naka-negative platelets to bind TSP before or after activation is unimpaired as compared with normal controls. These results do not support a role for GPIV as the TSP receptor.
糖蛋白IV(GPIV;CD36或GPIIIb)是一种细胞表面糖蛋白,有人提出它介导许多生理上重要的过程,如血小板与血小板反应蛋白(TSP)和胶原蛋白的黏附、恶性疟原虫感染红细胞的细胞黏附,以及单核细胞与血小板和巨噬细胞的TSP依赖性相互作用。由于最近发现中野阴性表型的血小板缺乏可检测到的GPIV,它们的存在为直接检验这些关于其黏附功能的假说提供了机会。已发现中野阴性血小板和单核细胞不支持恶性疟原虫感染红细胞的细胞黏附。中野阴性血小板在黏附于纤维状胶原蛋白的初始阶段存在缺陷,且这种缺陷在无镁(2+)条件下最为明显。最后,与正常对照相比,中野阴性血小板在激活前后结合TSP的能力未受损。这些结果不支持GPIV作为TSP受体的作用。